ly3016859
mAbexperimentalMulti-specific
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2012 (NCT01545583)
Timeline
Indications
Mechanism of action
- TNF-alphaINHIBITOR
TNF inhibitor
- ProepiregulinINHIBITOR
EREG inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- ly3016859
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04529096 | Phase 2 | Aug 25, 2020 | Eli Lilly |
| NCT04476108 | Phase 2 | Jul 15, 2020 | Eli Lilly |
| NCT04456686 | Phase 2 | Jul 1, 2020 | Eli Lilly |
| NCT05986292 | Phase 2 | Jan 30, 2020 | Eli Lilly |
| NCT01774981 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2013 | Eli Lilly |
| NCT01545583 | Phase 1 | Apr 1, 2012 | Eli Lilly |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 6 | 6 | 2 | 2012 |
1 organizations
Page 1 / 1